Saturday 17 October 2026
Export NMRA’s income statement to Excel — free account
Neumora Therapeutics, Inc.
NMRA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 30.3%, free cash flow grew 24.5% and total debt rose 172.0%, each against the same quarter a year earlier.
0.47
0.04
+9.30%
Follow NMRA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(104.35%) | (121.21%) | (148.74%) | (187.11%) | |
| (89.11%) | (93.28%) | (108.32%) | (121.89%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(156.16%) | (149.83%) | (180.29%) | (219.05%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.29) | (1.26) | (1.07) | (0.97) | |
Free Cash Flow |
(208.75) | (206.27) | (193.11) | (180.31) | |
Capital Expenditures |
0.07 | 0.17 | 0.29 | 0.21 | |
| Other line items | |||||
Cash ROIC |
(64.58%) | (60.50%) | (71.33%) | (84.16%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(28.59) | (34.17) | (43.97) | (32.71) | |
Operating CF/Net income |
0.88 | 0.87 | 0.87 | 0.85 | |
Depreciation/Fixed assets |
(44.02) | (37.92) | 1.28 | 40.64 | |
Capex/Depreciation |
(0.02) | (0.11) | 7.05 | 0.20 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.29) | (1.26) | (1.08) | (0.97) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates